|Systematic (IUPAC) name|
|ATC code||C01 R03
|Molecular mass||211.258 g/mol|
|(what is this?)|
Isoprenaline (INN) or isoproterenol (USAN, trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. It is a non-selective beta-adrenergic agonist and structurally similar to adrenaline.
It can be used as an inhaled aerosol to treat asthma, although this is currently a rare treatment. Although it activates all beta adrenergic receptors, it works in a similar fashion to the more selective β2-adrenergic agonists e.g. salbutamol, by relaxing the airways to increase airflow.
Isoprenaline is a β1- and β2-adrenoreceptor agonist which was commonly used to treat asthma before the more widespread use of albuterol, which has more selective effects on the airways. Its route of administration is either intravenous, oral, intranasal, subcutaneous, or intramuscular, depending on use. The plasma half-life for isoprenaline is approximately two minutes.
Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2--adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptor's vasodilation.
The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce an elevated heart rate (tachycardia), which predisposes patients to cardiac dysrhythmias.
Warnings and contraindications
Isoprenaline should not be administered to patients with myocardial ischemia.
According to Code of Federal Regulations (CFR) Title 21 Section 201.305, use of isoprenaline has been regulated by mandating the inclusion of the following warning label: "Occasional patients have been reported to develop severe paradoxical airway resistance with repeated, excessive use of isoprenaline inhalation preparations. The cause of this refractory state is unknown. It is advisable that in such instances the use of this preparation be discontinued immediately and alternative therapy instituted, since in the reported cases the patients did not respond to other forms of therapy until the drug was withdrawn. Deaths have been reported following excessive use of isoprenaline inhalation preparations and the exact cause is unknown. Cardiac arrest was noted in several instances"
Isoprenaline is synthesized by an analogous scheme of making epinephrine. Interaction of ω-chloro-3,4-dihydroxyacetophenone (chloroacetylpyrocatechol) with isopropylamine gives ω-isopropylamino-3,4-dihydroxyacetophenone, reduction of the carbonyl group of which by hydrogen using a palladium on carbon catalyst gives isoprenaline.
The isopropyl amine group in isoprenaline makes it selective for β receptors. The free catechol hydroxy groups keeps it susceptible to enzymatic metabolism.
An epidemic of deaths within a group of individuals who were being treated for asthma was detected between 1963 and 1968 in England, Wales, Scotland, Ireland, Australia, and New Zealand. This was later found to be largely attributed to isoprenaline inhalers which were being used at 5 times the dose USA and Canada were using it at, subsequently, USA and Canada did not add to this epidemic. Shortly after realizing overdose of the drug was causing many deaths, the medication was withdrawn and the number of asthmatics dying quickly decreased.
- Shen, Howard (2008). Illustrated Pharmacology Memory Cards: PharMnemonics. Minireview. p. 5. ISBN 1-59541-101-1.
- G. Schening, O. Thomae, US 723278 (1942)
- G. Schening, O. Thomae, U.S. Patent 2,308,232 (1943)
- Medicinal Chemistry of Adrenergics and Cholinergics
- Pierce, Neil and Hensley, Michael J. (1998). "Epidemiologic Studies of Beta Agonists and Asthma Deaths". Epidemiologic Studies 20 (2).